Johns Hopkins ABX Guide
Tipranavir
INDICATIONS
FDA
FDA
- Treatment of HIV+ pts with evidence of viral replication who are highly treatment-experienced or have HIV resistant to multiple PIs.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: January 23, 2023
Citation
Auwaerter, Paul G, and Paul A Pham. "Tipranavir." Johns Hopkins ABX Guide, The Johns Hopkins University, 2023. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540555/0/Tipranavir.
Auwaerter PG, Pham PA. Tipranavir. Johns Hopkins ABX Guide. The Johns Hopkins University; 2023. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540555/0/Tipranavir. Accessed July 27, 2025.
Auwaerter, P. G., & Pham, P. A. (2023). Tipranavir. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540555/0/Tipranavir
Auwaerter PG, Pham PA. Tipranavir [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2023. [cited 2025 July 27]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540555/0/Tipranavir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Tipranavir
ID - 540555
A1 - Auwaerter,Paul,M.D.
AU - Pham,Paul,Pharm.D.
Y1 - 2023/01/23/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540555/0/Tipranavir
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
